Millstone Evans Group’s Edwards Lifesciences EW Stock Holding History

Millstone Evans Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.4K	Buy	447 +57	+15%	+$4.78K	0.02%	388
2026 Q1	$31.2K	Hold	390	–	–	0.02%	415
2025 Q4	$33.2K	Hold	390	–	–	0.02%	404
2025 Q3	$30.3K	Hold	390	–	–	0.02%	404
2025 Q2	$30.5K	Hold	390	–	–	0.02%	393
2025 Q1	$28.3K	Hold	390	–	–	0.02%	397
2024 Q4	$28.9K	Buy	+390	New	+$27.3K	0.02%	380

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Millstone Evans Group's EW Position: Q2 2026 in Review

Millstone Evans Group increased its Edwards Lifesciences (EW) stake by 15% in Q2 2026, buying an estimated $4.78K and bringing the position to 447 shares worth $40.4K. The position accounts for 0.02% of the portfolio, ranked #388.

Millstone Evans Group first reported a position in EW in Q4 2024 and has held it in 7 quarters since. 1,096 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Millstone Evans Group held 447 shares of Edwards Lifesciences worth $40.4K as of Q2 2026.
Millstone Evans Group bought 57 Edwards Lifesciences shares in Q2 2026, an estimated $4.78K.
Edwards Lifesciences made up 0.02% of Millstone Evans Group's portfolio in Q2 2026, its #388 holding.
Millstone Evans Group first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 7 quarters since.
1,096 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.